Financial Snapshot

Revenue
$360.0K
TTM
Gross Margin
17.78%
TTM
Net Earnings
-$15.15M
TTM
Current Assets
Q2 2023
Current Liabilities
Q2 2023
Current Ratio
263.75%
Q2 2023
Total Assets
Q2 2023
Total Liabilities
$199.5K
Q2 2023
Book Value
$339.7K
Q2 2023
Cash
Q2 2023
P/E
-0.002641
Oct 22, 2024 EST
Free Cash Flow

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

No data

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Return On Shareholders' Equity

Book Value

Free Cash Flow

No data

Free Cash Flow YoY

No data

Free Cash Flow Margin

No data

Dividends

Dividends

No data

Stock Price

Market Cap: $40 Thousand

About ACRO BIOMEDICAL CO., LTD.

Acro Biomedical Co. Ltd. engages in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. The company is headquartered in Fishers, Indiana. The company went IPO on 2016-06-23. The firm is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The firm's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus, which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The firm is involved in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. The company sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.

Industry: Services-Amusement & Recreation Services Peers: AdaptHealth Corp. Fuse Medical, Inc. Cosmos Health Inc. Great Elm Group, Inc. MCKESSON CORP PATTERSON COMPANIES, INC. OWENS & MINOR INC/VA/ PetIQ, Inc.